FRANKLIN LAKES, N.J.,
April 6, 2017 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced it has received 510(k)
clearance from the U.S. Food and Drug Administration (FDA) for a
flow cytometer system with a leucocount reagent assay used in
residual white blood cell enumeration.
When used together with the BD Leucocount™ kit and BD Trucount™
tubes, the new BD FACSVia™ system provides a simple solution for
identifying and counting rWBCs in leucoreduced blood products.
"The BD FACSVia system provides blood banks and clinical
laboratories with an easy-to-use cell analysis solution to help
determine and quantify the presence of residual white blood cells
in their blood products," said John
Ledek, president of Biosciences for BD. "The addition of the
BD FACSVia system follows our larger strategy of making flow
cytometry easier to use with improved efficiency, simplified sample
analysis and high-quality diagnostic results."
With an intuitive user interface, the fully automated BD FACSVia
system improves overall lab efficiency and simplifies workflow.
The BD FACSVia system offers the performance of a full-function
clinical flow cytometer but in a compact design that easily fits on
a benchtop or within a hood.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has more than 40,000
associates across 50 countries who work in close collaboration with
customers and partners to help enhance outcomes, lower health care
delivery costs, increase efficiencies, improve health care safety
and expand access to health. For more information on BD, please
visit bd.com.
Contacts:
|
|
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
monique_dolecki@bd.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-receives-fda-510k-clearance-for-new-flow-cytometer-system-with-leucocount-reagent-assay-300435706.html
SOURCE BD (Becton, Dickinson and Company)